Breitfeld, J
Scholl, C
Steffens, M
Brandenburg, K
Probst-Schendzielorz, K
Efimkina, O
Gurwitz, D
Ising, M
Holsboer, F
Lucae, S
Stingl, J C
Article History
Received: 1 March 2016
Revised: 2 August 2016
Accepted: 3 August 2016
First Online: 15 November 2016
Competing interests
: FH is the founder and CEO of HMNC Brain Health GmbH Munich and holds two patents for the prediction of antidepressant treatment response by the ABCB1 gene (WO 2005/108605: Polymorphisms in ABCB1 associated with a lack of clinical response to medicaments; WO 2008/151803: New polymorphisms in ABCB1 associated with a lack of clinical response to medicaments). No writing assistance was utilized in the production of this manuscript. The remaining authors declare no conflict of interest.